Alzheimer's disease-Biomarkers, clinical evaluation or both?
作者信息
Simrén Joel, Ashton Nicholas J, Suárez-Calvet Marc, Zetterberg Henrik
机构信息
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
出版信息
J Neuropsychol. 2025 Jun;19(2):165-171. doi: 10.1111/jnp.12401. Epub 2024 Nov 14.
Abstract
摘要
相似文献
1
Alzheimer's disease-Biomarkers, clinical evaluation or both?阿尔茨海默病——生物标志物、临床评估还是两者兼顾？
J Neuropsychol. 2025 Jun;19(2):165-171. doi: 10.1111/jnp.12401. Epub 2024 Nov 14.
2
Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease.比较疑似阿尔茨海默病患者的 2-[18F]FDG-PET 和脑脊液生物标志物的临床影响。
PLoS One. 2021 Mar 12;16(3):e0248413. doi: 10.1371/journal.pone.0248413. eCollection 2021.
3
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.从 1984 年到 2014 年对阿尔茨海默病的临床试验和后期药物开发的评价。
J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191.
4
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization.用于生物标志物分类的常见阿尔茨海默病研究本体（CADRO）。
Alzheimers Dement (N Y). 2025 Feb 11;11(1):e70050. doi: 10.1002/trc2.70050. eCollection 2025 Jan-Mar.
5
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
6
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe.阿尔茨海默病中淀粉样蛋白和 tau 病理的诊断生物标志物：美国和欧洲临床实践中测试的概述。
J Prev Alzheimers Dis. 2023;10(3):426-442. doi: 10.14283/jpad.2023.43.
7
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用：系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
8
Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside.阿尔茨海默病中的脑脊液生物标志物——从脑淀粉样蛋白到实验室与临床应用
Diagnostics (Basel). 2017 Jul 13;7(3):42. doi: 10.3390/diagnostics7030042.
9
Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.临床前阿尔茨海默病生物标志物能准确预测认知和神经病理学结局。
Brain. 2022 Dec 19;145(12):4506-4518. doi: 10.1093/brain/awac250.
10
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍（MCI）患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
本文引用的文献
1
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.阿尔茨海默病协会全球生物标志物标准化联盟（GBSC）血浆磷酸化tau蛋白循环检验研究。
Alzheimers Dement. 2025 Feb;21(2):e14508. doi: 10.1002/alz.14508. Epub 2025 Feb 5.
2
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.用于阿尔茨海默病病理的主要血液检测的头对头比较。
Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.
3
A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer's disease.阿尔茨海默病诊断与分期修订标准的临床视角
Nat Aging. 2024 Aug;4(8):1029-1031. doi: 10.1038/s43587-024-00675-3.
4
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
5
Disease staging of Alzheimer's disease using a CSF-based biomarker model.采用基于脑脊液生物标志物模型对阿尔茨海默病进行疾病分期。
Nat Aging. 2024 May;4(5):694-708. doi: 10.1038/s43587-024-00599-y. Epub 2024 Mar 21.
6
CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease.脑脊液 p-tau205：阿尔茨海默病中 tau 病理的生物标志物。
Acta Neuropathol. 2024 Jan 6;147(1):12. doi: 10.1007/s00401-023-02659-w.
7
Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study.最佳血液 tau 标志物用于检测阿尔茨海默病神经病理学：免疫沉淀质谱法和尸检研究。
Acta Neuropathol. 2023 Dec 30;147(1):5. doi: 10.1007/s00401-023-02660-3.
8
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
9
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.CSF MTBR-tau243 是阿尔茨海默病中 tau 缠结病理的特异性生物标志物。
Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13.
10
Alzheimer's disease drug development pipeline: 2023.2023年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2023 May 25;9(2):e12385. doi: 10.1002/trc2.12385. eCollection 2023 Apr-Jun.
Zotero 插件